Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii

Eravacycline remains a key agent for the treatment of bacterial infections exhibiting promising efficacy against multidrug-resistant pathogens. As an empirical antibiotic it could be a good alternative for severe infections caused by CPE or CRAB, however, its clinical use is limited by the absence of standardized breakpoints. Resistance mechanisms, including efflux pumps and gene mutations, vary among isolates. High-risk clones like K. pneumoniae ST307 and A. baumannii ST2 underscore the necessity of prudent antibiotic use.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2024-12-01
DOI
https://doi.org/10.1016/j.biopha.2024.117666
Citations
9
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
1.53
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii

Cristina Lasarte-Monterrubio, Michelle Outeda-García, Juan Carlos Vázquez-Ucha, Patricia García et al.
9 citations
Biomedicine & Pharmacotherapy
Antibiotic Resistance in Bacteria
1.53
article

Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii

Cristina Lasarte-Monterrubio, Michelle Outeda-García, Juan Carlos Vázquez-Ucha, Patricia García, Alejandro Beceiro, Andrea Muras, Tania Blanco-Martín, Jorge Arca-Suárez, Romina Maceiras, Paula Guijarro-Sánchez, Isaac Alonso-García, Germán Bou, Lucía González-Pinto, Arianna Rodríguez-Coello, María del Carmen Fernández-López, Andrea García-Pose
article en
9 citations

Abstract

Eravacycline remains a key agent for the treatment of bacterial infections exhibiting promising efficacy against multidrug-resistant pathogens. As an empirical antibiotic it could be a good alternative for severe infections caused by CPE or CRAB, however, its clinical use is limited by the absence of standardized breakpoints. Resistance mechanisms, including efflux pumps and gene mutations, vary among isolates. High-risk clones like K. pneumoniae ST307 and A. baumannii ST2 underscore the necessity of prudent antibiotic use.

Biomedicine & PharmacotherapyVol. 181
Instituto de Investigación Biomédica de A Coruña (ES)
Openalex Percentile: Top 17%
Antibiotic Resistance in Bacteria
1.53
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii — Cristina Lasarte-Monterrubio, Michelle Outeda-García, et al. · Biomedicine & Pharmacotherapy (2024) | TGRS Research Map | TGRS